Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Filed May 2, 2024 · 10-Q · 32 days after period end · 0001178670-24-000023
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $494.33M | $319.29M | $213.26M | $177.57M |
| Net Income | -$65.94M | -$174.10M | -$240.34M | -$200.29M |
| EPS Diluted | -$0.52 | -$1.40 | -$2.00 | -$1.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end
